Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Passage BIO, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 56 | 1 | 51 | −4 |
| Shares | 33.4M | 23 | 32.4M | −978.2K (−2.9%) |
| Value | $31.4M | $22 | $21.3M | −$10.1M (−32.1%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Passage BIO, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 21,424 | $14.1K | 0.00% |
| Qube Research & Technologies Ltd | 4 | $3 | 0.00% |
Sold out (6)
Institutions that held Passage BIO, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Annandale Capital, LLC | 54,338 | $51.0K |
| Cornercap Investment Counsel Inc | 49,767 | $46.8K |
| Deutsche Bank AG | 24,697 | $23.2K |
| Veritable, L.P. | 23,045 | $21.7K |
| Two Sigma Securities, LLC | 20,608 | $19.4K |
| Clearstead Advisors, LLC | 75 | $71 |
Not filed for Q3 2023 yet (1)
Institutions that held Passage BIO, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| First Capital Advisors Group, LLC. | 23 | $22 |